Boosting NAD(+) for the prevention and treatment of liver cancer.
Hepatocellular carcinoma (HCC) is the third leading cause of cancer death worldwide yet has limited therapeutic options. We recently demonstrated that inhibition of de novo nicotinamide adenine dinucleotide (NAD(+)) synthesis is responsible for DNA damage, thereby initiating hepatocarcinogenesis. We propose that boosting NAD(+) levels might be used as a prophylactic or therapeutic approach in HCC.
Cancer Cell Biology Programme; Growth Factors, Nutrients and Cancer Group; Spanish National Cancer Research Centre ; Madrid, Spain.
Nabil
N
Djouder
Aryl hydrocarbon receptor (AhR); DNA damage; Estrogen receptor (ER); GEMMs; HCC; NAD+; URI; nicotinamide riboside; pancreatic tumor; prevention; therapy